Title : KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Pub. Date : 2011

PMID : 21894049






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. gemcitabine KRAS proto-oncogene, GTPase Homo sapiens